sprite-preloader
Anzeige
Mehr »
Freitag, 22.06.2018 Börsentäglich über 12.000 News von 586 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: 904217 ISIN: IL0010811169 Ticker-Symbol: ELD 
Aktie:
Branche
Sonstige Technologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ELBIT IMAGING LTD Chart 1 Jahr
1-Woche-Intraday-Chart
ELBIT IMAGING LTD 1-Woche-Intraday-Chart
14.03.2018 | 18:56
(5 Leser)
Schrift ändern:
(0 Bewertungen)

ACCESSWIRE·Mehr Nachrichten von ACCESSWIRE

TEL AVIV, ISRAEL / ACCESSWIRE / March 14, 2018 / Elbit Imaging Ltd. ('EI' or the 'Company') (TASE: EMITF; NASDAQ: EMITF) announced today, further to its previous press release dated February 28, 2018, that the Series H bondholders meeting voted against the full early redemption (the 'Redemption') of the Series H notes (the 'Notes') and therefore the Redemption will not be executed and the Notes will be repaid on May 31, 2018.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) development of shopping and entertainment centers in emerging markets; (ii) medical industries and devices for: (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment; and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; and (iii) land in India designated for sale to residential projects.

For Further Information:

Company Contact
Ron Hadassi

Chief Executive Officer & Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com

SOURCE: Elbit Imaging Ltd.


© 2018 ACCESSWIRE